Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1

Paul Krogstad; Sophia Lee; George Johnson; Kenneth Stanley; James McNamara; John Moye; J Brooks Jackson; Rosaura Aguayo; Arry Dieudonne; Margaret Khoury; Hermann Mendez; Sharon Nachman; Andrew Wiznia

doi:10.1086/338814

Back

Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1

Journal article

Peer reviewed

Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1

Paul Krogstad, Sophia Lee, George Johnson, Kenneth Stanley, James McNamara, John Moye, J Brooks Jackson, Rosaura Aguayo, Arry Dieudonne, Margaret Khoury, …

Clinical infectious diseases, Vol.34(7), pp.991-1001

04/01/2002

DOI: 10.1086/338814

PMID: 11880966

View Online

Abstract

The relative potency and tolerability of multidrug regimens used to treat infants and children infected with human immunodeficiency virus type 1 (HIV-1) are largely unknown. In Pediatric AIDS Clinical Trials Group (PACTG) Protocol 377, 181 infants and children were assigned to receive stavudine (d4T) plus nevirapine (NVP) and ritonavir (RTV); d4T plus lamivudine (3TC) and nelfinavir (NFV); d4T plus NVP and NFV; or d4T plus 3TC, NVP, and NFV. Eleven additional children received d4T and NVP plus NFV given twice daily. All subjects had not previously received protease inhibitors or nonnucleoside reverse-transcriptase inhibitors and all had been immunologically stable while receiving reverse-transcriptase inhibitor therapy. After 48 weeks of therapy, 17 (41%) of 41 subjects receiving d4T-NVP-RTV, 13 (30%) of 44 receiving d4T-NVP-NFV, 21 (42%) of 50 receiving d4T-3TC and NFV (3 times daily), and 22 (52%) of 42 receiving d4T-3TC-NVP-NFV were still receiving their assigned therapy and had HIV-1 RNA suppression to </= 400 copies/mL. These regimens were similar in their drug activity, but the 4-drug regimen offered slightly more durable suppression of viremia.

HIV-1

Nelfinavir - therapeutic use

Anti-HIV Agents - adverse effects

Humans

Child, Preschool

Male

Nevirapine - therapeutic use

Nevirapine - adverse effects

Nelfinavir - adverse effects

Reverse Transcriptase Inhibitors - adverse effects

Ritonavir - adverse effects

Stavudine - therapeutic use

Lamivudine - therapeutic use

Ritonavir - therapeutic use

Anti-HIV Agents - therapeutic use

Female

HIV Infections - drug therapy

RNA, Viral - metabolism

Reverse Transcriptase Inhibitors - therapeutic use

Drug Therapy, Combination

RNA, Viral - drug effects

Child

CD4-Positive T-Lymphocytes - drug effects

Details

Title: Subtitle: Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1
Creators: Paul Krogstad - University of California, Los Angeles School of Medicine, Departments of Pediatrics and Molecular and Medical Pharmacology, Los Angeles, CA, 90095, USA. pkrogstad@mednet.ucla.edu
Sophia Lee
George Johnson
Kenneth Stanley
James McNamara
John Moye
J Brooks Jackson
Rosaura Aguayo
Arry Dieudonne
Margaret Khoury
Hermann Mendez
Sharon Nachman
Andrew Wiznia
Resource Type: Journal article
Publication Details: Clinical infectious diseases, Vol.34(7), pp.991-1001
DOI: 10.1086/338814
PMID: 11880966
NLM abbreviation: Clin Infect Dis
ISSN: 1058-4838
eISSN: 1537-6591
Publisher: United States
Grant note: AI-41110 / NIAID NIH HHS
Language: English
Date published: 04/01/2002
Academic Unit: Pathology; VPMA - Administration; Internal Medicine
Record Identifier: 9984047699702771

Metrics

20 Record Views

50 Times Cited - Web of Science

See more details